Samsung Life Science Fund

Samsung Life Science Fund is a strategic investment fund, deploying capital into early to late-stage biotechnology companies. It supports the development of novel therapeutic modalities and precision biologics, including advanced Antibody-Drug Conjugates (ADCs). Its portfolio targets companies engaged in preclinical and clinical development, aiming to accelerate scientific innovation into medical solutions.

The fund was jointly established by Samsung Biologics, Samsung Bioepis, and Samsung C&T, with Samsung Ventures managing operations. This collaborative structure leverages Samsung's resources and expertise to foster growth in the global life sciences ecosystem. Its creation reflects a strategic commitment to expanding beyond traditional manufacturing into innovative biopharmaceutical research.

Samsung Life Science Fund partners with innovative biopharmaceutical companies, providing financial and strategic support for pipeline advancement. Its overarching vision is to address unmet medical needs and improve patient outcomes globally. Diversifying investments across promising next-generation therapeutic platforms, the fund aims to deliver meaningful impact on global health challenges.